Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
QScreen AI (OTC:PMEDF) elected to move from quarterly to semi-annual financial reporting under Canadian CBO 51-933 for eligible venture issuers. The company aims to reduce administrative and financial reporting burden and redirect resources toward core business objectives.
The first period without quarterly disclosure is the three months ended April 30, 2026. The next scheduled filing will cover the six-month interim period ending July 31, 2026. QScreen AI will continue to file audited annual and six-month interim financial statements with MD&A and comply with all continuous disclosure requirements, including reporting material changes.
QScreen AI (OTC: PMEDF) closed the first tranche of its non-brokered private placement, issuing 4,876,400 units at $0.05 for gross proceeds of about $243,820.
Each unit includes one share and half a warrant exercisable at $0.07 for 36 months. Funds will support commercialization, business development, technology advancement, market expansion and working capital.
QScreen AI (OTC Pink: PMEDF) will hold a five-city investor roadshow across Central Europe from June 1–5, 2026, visiting Munich, Ljubljana, Budapest, Bratislava, and Vienna.
Recent milestones include integrating passive voice analysis, surpassing 720,000 physiological scans, adding senior advisors, and expanding a patent-backed, multi-modal screening platform.
QScreen AI (OTC: PMEDF) appointed retired Lieutenant General Michael S. Groen, former Director of the Pentagon’s Joint Artificial Intelligence Center, to its Advisory Board after a live platform demonstration on May 11, 2026.
The proprietary physiological AI screening platform analyzes 34 physiological signals and 13 clinical instruments via standard cameras and voice to identify probable impairment patterns, substance classes, and certain withdrawal states. Groen, alongside Global Frontier Advisors, is expected to support commercialization across correctional health, national defense, transportation, and federal security markets in North America.
QScreen AI (OTC: PMEDF) announced integration of a passive voice analysis engine into its multi-signal screening platform on May 6, 2026. The system now reads physiological, acoustic, and behavioral signals simultaneously using existing device microphones and camera data, with individualized longitudinal baselining and no added hardware or workflow changes.
The platform measures voice features such as response latency, speech rate, vocal tremor and pitch against each person’s prior baseline, and is positioned for correctional intake, pre-shift fitness-for-duty screening and addiction rehabilitation deployments.
QScreen AI (OTC: PMEDF) reported internal validation of its correctional intake platform across 65 calibrated clinical scenarios, validating nine instruments versus published thresholds. Key results include 100% sensitivity and specificity for Columbia C-SSRS suicide risk and CIWA-Ar/COWS withdrawal, plus an active 60-day pilot plan and no specialized hardware required for deployment.
QScreen AI (OTC: PMEDF) appointed José Humberto "Beto" Vargas García as Strategic Advisor to accelerate entry into North American rail and transportation markets. Mr. Vargas brings 25 years of senior commercial relationships across Class I railroads and former Vice President experience at Union Pacific, managing a USD $2.8 billion commercial portfolio. The company says its QAI Platform uses camera-captured physiological signals to identify probable drug use in real time without blood, breath, or urine samples. The release also notes a change of auditor.
QScreen AI (OTC:PMEDF) completed its patent‑protected QAI physiological AI clinical platform that identifies probable substance class (alcohol, opioid, benzodiazepine, stimulant, cannabis) from a standard laptop camera and runs 13 validated clinical instruments in under seven minutes with no hardware or IT project.
The platform processed >720,000 real‑world scans and the company is pursuing evaluation agreements with correctional health and US defense verticals, targeting a 300–500 facility pipeline while engaging Global Frontier Advisors led by Lt. Gen. Michael S. Groen (Ret.).
QScreen AI (OTC Pink: PMEDF) announced a non‑brokered private placement to issue up to 10,000,000 units at C$0.05 per Unit for aggregate gross proceeds of up to C$500,000. Each Unit includes one common share and one half warrant; each warrant allows purchase of one half share at C$0.15 for 36 months.
Proceeds will fund structured pilot discussions, operational integration planning and working capital to scale commercialization across healthcare, industrial and technology sectors, building on recent trade mission activity in Mexico.
QScreen AI (OTC: PMEDF) reported substantive commercialization discussions during the Government of Canada trade mission to Mexico on February 23, 2026. The company held structured one-on-one meetings across healthcare, defense, advanced manufacturing, agri-food, infrastructure, and AI ecosystems.
Discussions advanced to defined follow-up talks to shape pilot scope, deployment parameters, and integration requirements; definitive agreements remain subject to customary commercial evaluation and approvals. The company noted a recent U.S. patent filing and said Mexico represents a sizable addressable opportunity for enterprise-scale Quantum-AI screening solutions.